Thu April 2, 2020 8:00 AM|Business Wire|About: HZNP

-- Gained Rights to Product Candidate, CZN001 (renamed HZN-825), a Potential Treatment for Diffuse Cutaneous Systemic Sclerosis; a Rare Rheumatic Disease with No FDA-Approved Treatment --

-- Compelling Fit with Horizon’s Strategy to Acquire and Develop Medicines Targeting Diseases with High Unmet Need with Focus on Its Core Therapeutic Areas --

DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP)

 https://www.horizontherapeutics.com/ 

 https://www.horizontherapeutics.com/our-pipeline/ 

 https://www.businesswire.com/news/home/20200402005203/en/ 

 https://seekingalpha.com/symbol/HZNP 

Fri April 3, 2020 6:59 AM|PR Newswire|About: BDXPR Newswire

FRANKLIN LAKES, N.J. and BIRMINGHAM, Ala., April 3, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company (BDX)) (NYSE: BDX), a leading global medical technology company, and BioGX Inc.

 https://www.bd.com/en-us 

 http://biogx.com/ 

 https://www.prnewswire.com/news-releases/bd-biogx-announce-fda-emergency-use-authorization-for-new-covid-19-diagnostic-for-use-in-us-301034652.html 

 https://seekingalpha.com/symbol/BDX 

 http://biogx.com/news/becton-dickinson-biogx-get-fda-emergency-use-authorization-for-rapid-sars-cov-2-test 

 https://biogx.com/ 

Mon April 6, 2020 8:01 AM|GlobeNewswire|About: GSK, VIR

• Companies will combine their unique scientific and technical expertise to combat COVID-19 and potential future coronavirus outbreaks
  
  
• Promising antibody candidates for SARS-CoV-2 to be accelerated into phase 2 clinical trials within the next three to five months
  
  
• GSK to make equity investment of $250 million in Vir

LONDON and SAN FRANCISCO, April 06, 2020 (GLOBE NEWSWIRE) -- LSE announcement -- GlaxoSmithKline plc (GSK) and Vir Biotechnology, Inc. (VIR)

 https://www.vir.bio/ 

 https://www.vir.bio/science/#programs 

 https://investors.vir.bio/news-releases/news-release-details/gsk-and-vir-biotechnology-enter-collaboration-find-coronavirus 

 https://seekingalpha.com/symbol/GSK 

 https://seekingalpha.com/symbol/VIR 

Mon April 6, 2020 6:15 AM|Business Wire|About: GILD

-- Multi-year, Multi-program Agreement Leverages Latest Insights of Microbiome --

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) and Second Genome

 https://www.businesswire.com/news/home/20200406005220/en/ 

 https://www.secondgenome.com/ 

 https://seekingalpha.com/symbol/GILD 

 https://www.gilead.com/news-and-press/press-room/press-releases/2020/4/gilead-sciences-and-second-genome-announce-strategic-collaboration-in-biomarker-and-inflammatory-bowel-disease-drug-discovery 

Mon April 6, 2020 7:00 AM|Business Wire|About: ALNY, DRNA

- Dicerna to Lead Global Clinical Development and U.S. Commercialization of its DCR-A1AT and Alnylam’s ALN-AAT02 Investigational Therapeutics for the Treatment of Alpha-1 Liver Disease; Alnylam Retains Post-Phase 3 Opt-in Right for Ex-U.S. Commercialization -

- Companies Complete Non-Exclusive Intellectual Property Cross-License Agreement for the Development and Commercialization of Alnylam’s Lumasiran and Dicerna’s Nedosiran Investigational Programs for Primary Hyperoxaluria -

CAMBRIDGE, Mass. & LEXINGTON, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (ALNY) (Nasdaq: ALNY), and Dicerna Pharmaceuticals, Inc. (DRNA) (Nasdaq: DRNA)

 https://www.alnylam.com/ 

 https://www.alnylam.com/alnylam-rnai-pipeline/ 

 https://seekingalpha.com/symbol/ALNY 

 https://dicerna.com/ 

 https://dicerna.com/pipeline/ 

 https://seekingalpha.com/symbol/DRNA 

 https://www.businesswire.com/news/home/20200406005200/en/ 

 Alpha-1 antitrypsin deficiency 

 https://ghr.nlm.nih.gov/condition/alpha-1-antitrypsin-deficiency# 

 Primary hyperoxaluria 

 https://ghr.nlm.nih.gov/condition/primary-hyperoxaluria 

Mon March 30, 2020 7:00 AM|Business Wire|About: VIRQ4: 03-26-20 Earnings SummaryEPS of $-0.69 misses by $-0.06 Revenue of $0.98M (-% Y/Y) misses by $-1.59M

CAMBRIDGE, Mass. & SAN FRANCISCO--(BUSINESS WIRE)-- Generation Bio and Vir Biotechnology (VIR) (Nasdaq: VIR) 

 https://www.businesswire.com/news/home/20200330005148/en/ 

 https://www.vir.bio/ 

 https://generationbio.com/ 

 https://seekingalpha.com/symbol/VIR 

 https://www.vir.bio/pipeline/ 

Tue March 31, 2020 6:30 AM|PR Newswire|About: LLY

INDIANAPOLIS and OXFORD, England, March 31, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY) today announced an exclusive global licensing and research collaboration with Sitryx,

 https://www.prnewswire.com/news-releases/lilly-and-sitryx-announce-licensing-and-research-collaboration-to-discover-and-develop-new-immunometabolic-medicines-301032137.html 

 http://www.sitryx.com/ 

 http://www.sitryx.com/news-and-events/press-releases/2020/ 

 https://seekingalpha.com/symbol/LLY 

Tue March 31, 2020 7:30 AM|Newsfile|About: NNVCNewsfile Corp

The Company's Update on its Development of COVID-19 Drug Candidate is Promising

Vancouver, British Columbia--(Newsfile Corp. - March 31, 2020) - NanoViricides, Inc. (NNVC) (

 http://www.nanoviricides.com/ 

 http://www.nanoviricides.com/pipeline.html 

 https://smallcapsdaily.com/nanoviricides-the-latest-covid-19-drug-update-looks-promising/ 

 https://seekingalpha.com/symbol/NNVC 

Tue March 31, 2020 2:00 PM|GlobeNewswire|About: SRNE

SAN DIEGO, March 31, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE), announced it has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento’s COVID-19 therapeutic product candidates.

 https://sorrentotherapeutics.com/ 

 https://som.utmb.edu/ 

 Immuno-Oncology 

 https://sorrentotherapeutics.com/pipeline/ 

 https://seekingalpha.com/symbol/SRNE 

Tue March 31, 2020 4:05 PM|PR Newswire|About: RARE, RGNX

PR Newswire

ROCKVILLE, Md. and NOVATO, Calif., March 31, 2020 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, and Ultragenyx Pharmaceutical Inc. (RARE),

 https://www.ultragenyx.com/ 

 https://www.regenxbio.com/ 

 https://www.ultragenyx.com/pipeline/ 

 https://www.regenxbio.com/therapeutic-programs/ 

 https://seekingalpha.com/symbol/RGNX 

 https://seekingalpha.com/symbol/RARE 

Tue March 31, 2020 4:05 PM|GlobeNewswire|About: EBS, NVAX

• CDMO agreement for NanoFlu to support pathway to licensure
  
• Expanded collaboration now includes NanoFlu and COVID-19 vaccine candidate

GAITHERSBURG, Md., March 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (EBS) today announced an agreement with Novavax, Inc. (NVAX) 

 https://www.emergentbiosolutions.com/ 

 https://novavax.com/ 

 https://www.emergentbiosolutions.com/pipeline 

 https://novavax.com/page/8/vaccine-technology.html 

 https://seekingalpha.com/symbol/NVAX 

 https://seekingalpha.com/symbol/EBS 

 https://novavax.com/page/11/clinical-stage-pipeline.html 

Tue March 24, 2020 9:32 AM|GlobeNewswire|About: SRNE

• ACE-MABTM is a proprietary bi-specific fusion protein that binds to the spike protein of coronaviruses, including SARS-CoV-2 and SARS-CoV, which is expected to block SARS-CoV-2 from binding and infecting respiratory epithelial cells or ACE2-expressing cells to interrupt the viral life cycle
  
• ACE-MAB is in the cGMP cell line development stage by our strategic partner, Mabpharm Limited, and could be ready for large-scale production in Mabpharm’s 30,000 m2 cGMP facilities in China for human clinical trials and commercialization upon receipt of requisite regulatory approvals
• Sorrento has been granted an exclusive license to develop and commercialize the ACE-MAB product candidate in the North American and European markets

SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE) today announced it has entered into an exclusive license agreement with China-based antibody biopharmaceutical company, Mabpharm Limited (Hong Kong Stock Exchange: 2181HK,

 https://sorrentotherapeutics.com/ 

 http://www.mabpharm.cn/en/index.php 

 https://sorrentotherapeutics.com/pipeline/ 

 https://seekingalpha.com/symbol/SRNE 

 https://apnews.com/Globe%20Newswire/5a08618b12f6f2f70ac2bc199b48324a 

 http://www.mabpharm.cn/en/research_product.php 

Wed March 25, 2020 11:43 PM|Business Wire|About: BABA

HANGZHOU, China--(BUSINESS WIRE)

 https://www.alibabacloud.com/solutions/dingtalk/international-medical-expert-communication-platform?spm=a3c0i.14157329.6596852130.2.1bf2772d5A46tB 

 https://covid-19.alibabacloud.com/#J_8102420620 

International Medical Expert Communication Center
Is Officially Launched

 https://covid-19.alibabacloud.com/ 

 https://covid-19.alibabacloud.com/ 

 https://www.businesswire.com/news/home/20200325005799/en/ 

 https://seekingalpha.com/symbol/BABA 

Thu March 26, 2020 7:30 AM|GlobeNewswire|About: DVAXGlobeNewswire

EMERYVILLE, Calif., March 26, 2020 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (DVAX) (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI)

 https://www.dynavax.com/ 

 https://cepi.net/ 

 https://www.fda.gov/ 

 http://investors.dynavax.com/node/17866/pdf 

 https://seekingalpha.com/symbol/DVAX 

 http://investors.dynavax.com/news-releases/news-release-details/dynavax-and-cepi-announce-collaboration-support-global-effort 

Fri March 27, 2020 2:00 AM|GlobeNewswire|About: SNY, TBIO

The two companies will jointly investigate multiple candidates with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development

PARIS and LEXINGTON, Mass., March 27, 2020 (GLOBE NEWSWIRE) -- Sanofi Pasteur, the vaccines global business unit of Sanofi (SNY), and Translate Bio (TBIO)

 https://translate.bio/ 

 https://seekingalpha.com/symbol/SNY 

 https://seekingalpha.com/symbol/TBIO 

 https://www.sanofi.com/ 

 https://www.sanofi.com/en/media-room/press-releases/2020/2020-03-27-07-00-00 

Thu March 26, 2020 4:30 PM|GlobeNewswire|About: TBIO

-- FDA grants Rare Pediatric Disease designation for MRT5005 for treatment of cystic fibrosis –

 -- Response to COVID-19 pandemic anticipated to cause interruptions in certain clinical trial operations; updated interim data readout timing to be provided at later date --

LEXINGTON, Mass., March 26, 2020 (GLOBE NEWSWIRE) -- Translate Bio (TBIO)

 https://seekingalpha.com/pr/17820487-translate-bio-provides-mrt5005-program-updates 

 https://translate.bio/pipeline/ 

Mon March 30, 2020 7:22 AM|PR Newswire|About: JNJ

Johnson & Johnson (JNJ) and BARDA

 https://www.janssen.com/infectious-diseases-and-vaccines/patented-technologies 

 https://www.jnj.com/coronavirus 

 https://www.jnj.com/ 

 https://www.prnewswire.com/news-releases/johnson--johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-us-department-of-health--human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use-301031582.html 

 https://seekingalpha.com/symbol/JNJ 

 https://www.jnj.com/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-u-s-department-of-health-human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic-use 

. 

Mon March 30, 2020 8:15 AM|GlobeNewswire|About: MDT

DUBLIN, March 30, 2020 (GLOBE NEWSWIRE) --  Medtronic plc (MDT) (NYSE:MDT)

 https://www.fda.gov/media/136318/download 

 https://www.medtronic.com/us-en/index.html 

 http://newsroom.medtronic.com/news-releases/news-release-details/medtronic-shares-ventilation-design-specifications-accelerate 

 https://seekingalpha.com/symbol/MDT 

Fri March 13, 2020 9:41 AM|PR Newswire|About: JNJPR Newswire

NEW BRUNSWICK, N.J., March 13, 2020 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced that its Janssen Pharmaceutical Companies have entered a collaboration with the Beth Israel Deaconess Medical Center (BIDMC) 

 Cutting-edge technologies are the driving force behind our strong research and development pipeline 

 https://www.janssen.com/infectious-diseases-and-vaccines/patented-technologies 

 https://seekingalpha.com/symbol/JNJ 

Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine

Janssen joins forces with Biomedical Advanced Research and Development Authority (BARDA) to protect communities against threat of a global COVID-19 pandemic

 https://www.jnj.com/johnson-johnson-announces-collaboration-with-u-s-department-of-health-human-services-to-accelerate-development-of-a-potential-novel-coronavirus-vaccine 

 https://www.jnj.com/coronavirus 

 https://www.jnj.com/johnson-johnson-launches-multi-pronged-response-to-coronavirus-global-public-health-threat 

Mon March 16, 2020 7:30 AM|PR Newswire|About: ACRX

PR Newswire

REDWOOD CITY, Calif., March 16, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) 

 https://www.acelrx.com/ 

 https://www.tphase.com/# 

 https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-acquire-tetraphase-pharmaceuticals-301024578.html 

 https://www.tphase.com/products/xerava/ 

 https://seekingalpha.com/symbol/ACRX 

Wed March 18, 2020 6:00 AM|PR Newswire|About: IDYA, PFEPR Newswire

SOUTH SAN FRANCISCO, Calif., March 18, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (IDYA),

 https://www.prnewswire.com/news-releases/ideaya-and-pfizer-enter-clinical-trial-collaboration-and-supply-agreement-to-evaluate-clinical-combination-of-ide196-and-binimetinib-in-solid-tumors-harboring-gnaq-or-gna11-hotspot-mutations-301025907.html 

 https://www.ideayabio.com/ 

 https://seekingalpha.com/symbol/IDYA 

 https://seekingalpha.com/symbol/PFE 

 https://clinicaltrials.gov/ct2/show/NCT03947385?term=ideaya&draw=2&rank=1 

Thu March 19, 2020 6:50 PM|PR Newswire|About: DHR, GE

WASHINGTON, March 19, 2020 /PRNewswire/ -- Danaher Corporation (DHR)

 https://www.danaher.com/ 

 https://www.prnewswire.com/news-releases/danaher-receives-clearance-from-us-federal-trade-commission-for-the-acquisition-of-the-biopharma-business-of-general-electric-life-sciences-301027237.html 

 https://seekingalpha.com/symbol/DHR 

Mon March 23, 2020 7:00 AM|GlobeNewswire|About: ACIU

• CHF 10 million milestone recognizes development progress
  
• Updated financial terms add a new CHF 60 million milestone for Phase 2 initiation
• Total potential deal value is now CHF 1.86 billion, up from CHF 1.82 billion

LAUSANNE, Switzerland, March 23, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU) (NASDAQ: ACIU)

 https://www.acimmune.com/ 

 https://www.lilly.com/ 

 https://ir.acimmune.com/news-releases/news-release-details/ac-immune-and-lilly-announce-license-and-collaboration-agreement?field_nir_news_date_value%5bmin%5d=2019 

 https://ir.acimmune.com/news-releases/news-release-details/ac-immune-initiates-phase-1-study-aci-3024-small-molecule-tau?field_nir_news_date_value%5bmin%5d=2019 

 https://seekingalpha.com/symbol/ACIU 

 https://seekingalpha.com/symbol/LLY 

Tue March 24, 2020 8:00 AM|PR Newswire|About: LLY

INDIANAPOLIS, March 24, 2020 /PRNewswire/

 https://www.prnewswire.com/news-releases/updates-from-lilly-about-insulin-supply-and-affordability-301028654.html 

9th edition 2019 

 https://diabetesatlas.org/en/ 

 https://www.lilly.com/ 

 https://www.facebook.com/LillyDiabetesUS/ 

 https://www.lillydiabetes.com/ 

 https://seekingalpha.com/symbol/LLY 

Wed March 11, 2020 8:00 AM|GlobeNewswire|About: VIRGlobeNewswire

SAN FRANCISCO, March 11, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology (VIR), Inc. (Nasdaq: VIR)

 https://www.vir.bio/ 

 https://seekingalpha.com/symbol/VIR 

 https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-announces-research-collaboration-national 

03/12/20 at 8:00 AM EDTPDF Version

SAN FRANCISCO, March 12, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it has signed a letter of intent with Biogen Inc. (Nasdaq: BIIB)

Mar. 12, 2020 8:40 AM ET|About: Vir Biotechnology, Inc. (VIR)|By: Douglas W. House, SA News Editor 

 https://seekingalpha.com/news/3551009-vir-biotech-up-27-premarket-on-covidminus-19-deal-biogen 

Thu March 12, 2020 7:00 AM|PR Newswire|About: STRO

SOUTH SAN FRANCISCO, Calif., March 12, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (STRO)

 https://www.sutrobio.com/ 

 https://www.prnewswire.com/news-releases/sutro-biopharma-announces-extension-of-first-cytokine-derivative-research-program-under-collaboration-with-merck-301022013.html 

 https://seekingalpha.com/symbol/STRO 

 https://seekingalpha.com/symbol/MRK 

Thu March 12, 2020 7:00 AM|PR Newswire

CARLSBAD, Calif., March 12, 2020 /PRNewswire/ -- Thermo Fisher Scientific

 https://www.thermofisher.com/us/en/home.html 

 http://thermofisher.mediaroom.com/2020-03-12-Thermo-Fisher-Scientific-Signs-Agreement-with-Janssen-to-Co-Develop-Companion-Diagnostic-for-Cancer 

 https://www.prnewswire.com/news-releases/thermo-fisher-scientific-signs-agreement-with-janssen-to-co-develop-companion-diagnostic-for-cancer-301022011.html 

 https://seekingalpha.com/symbol/TMO 

 https://seekingalpha.com/symbol/JNJ 

Wed March 11, 2020 10:45 AM|GlobeNewswire|About: NVAX

• Novavax’ proprietary Matrix-M vaccine adjuvant enhances immune response of malaria antigen developed at Jenner Institute at Oxford University
  
• Phase 2b clinical efficacy study of experimental malaria vaccine with Matrix‑M nearing completion in Burkina Faso

GAITHERSBURG, Md., March 11, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX)

 https://www.who.int/publications-detail/world-malaria-report-2019 

 https://www.novavax.com/ 

 https://www.seruminstitute.com/ 

 https://www.novavax.com/page/11/clinical-stage-pipeline.html 

 https://seekingalpha.com/symbol/NVAX 

Thu March 12, 2020 6:11 PM|PR Newswire|About: LLYPR Newswire

VANCOUVER, British Columbia and INDIANAPOLIS, March 12, 2020 /PRNewswire/ -- AbCellera and Eli Lilly and Company (LLY)

 https://www.abcellera.com/ 

 https://www.abcellera.com/news/2020-03-abcellera-and-lilly-codevelopment 

 https://www.lilly.com/ 

 https://www.prnewswire.com/news-releases/abcellera-and-lilly-to-co-develop-antibody-therapies-for-the-treatment-of-covid-19-301022689.html 

 https://investor.lilly.com/news-releases/news-release-details/abcellera-and-lilly-co-develop-antibody-therapies-treatment 

 https://seekingalpha.com/symbol/LLY 

Mon March 2, 2020 4:30 PM|PR Newswire|About: CVS

WOONSOCKET, R.I. and SAN JOSE, Calif., March 2, 2020 /PRNewswire/ -- CVS Kidney Care, a CVS Health (CVS) company, and Satellite Healthcare 

 https://www.cvshealth.com/ 

 https://www.satellitehealth.com/ 

 https://www.prnewswire.com/news-releases/cvs-kidney-care-satellite-healthcare-enter-strategic-relationship-to-advance-the-care-of-patients-with-kidney-disease-301014761.html 

 https://seekingalpha.com/symbol/CVS 

Tue March 3, 2020 2:53 AM|PR Newswire|About: QGEN, TMO

PR Newswire

WALTHAM, Mass. and VENLO, Netherlands, March 3, 2020 /PRNewswire/ -- Thermo Fisher Scientific Inc. (TMO), the world leader in serving science, and QIAGEN N.V. (QGEN)

 https://www.thermofisher.com/us/en/home.html 

 https://www.qiagen.com/us/ 

 https://www.prnewswire.com/news-releases/thermo-fisher-scientific-to-acquire-qiagen-nv-301015072.html 

 https://seekingalpha.com/symbol/QGEN 

 https://seekingalpha.com/symbol/TMO 

 http://thermofisher.mediaroom.com/2020-03-03-Thermo-Fisher-Scientific-to-Acquire-QIAGEN-N-V,1 

Mar. 3, 2020 9:09 AM ET|About: AstraZeneca PLC (AZN)|By: Douglas W. House, SA News Editor 

 https://seekingalpha.com/symbol/AZN 

 https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-recover-the-global-rights-to-brazikumab-medi2070-from-allergan-27012020.html 

Tue March 3, 2020 5:30 PM|Business Wire|About: BMY

NEW YORK & PARIS--(BUSINESS WIRE)-- Regulatory News:

Voluntis (Paris:VTX) (Euronext Paris, Ticker: VTX - ISIN: FR0004183960), a leader in digital therapeutics, and Bristol-Myers Squibb Company (BMY)

 http://www.voluntis.com/ 

 https://www.businesswire.com/news/home/20200303006062/en/ 

 https://news.bms.com/press-release/httpwwwvoluntiscomennewsnews-12020voluntis-and-bristol-myers-squibb-co-develop-digital 

 https://seekingalpha.com/symbol/BMY 

Tue March 3, 2020 5:50 PM|Business Wire|About: ACAD 

 https://www.businesswire.com/news/home/20200303006075/en/ 

 https://www.acadia-pharm.com/ 

 https://www.acadia-pharm.com/pipeline/rett-syndrome/ 

 https://ir.acadia-pharm.com/news-releases/news-release-details/acadia-pharmaceuticals-and-neuren-pharmaceuticals-announce-rare?field_nir_news_date_value[min]= 

 https://seekingalpha.com/symbol/ACAD 

Wed March 4, 2020 7:00 AM|Business Wire|About: ALNY, VIR

 — Recent Alnylam (ALNY) advances in lung delivery technology suggest possible utility of siRNAs in targeting SARS-CoV-2 and other coronaviruses

— Vir to lead development of potential coronavirus RNAi therapeutic candidates, with Alnylam retaining an option for 50-50 participation

SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (VIR) and Alnylam Pharmaceuticals, Inc.

 https://www.vir.bio/ 

 https://www.alnylam.com/ 

 https://www.businesswire.com/news/home/20200304005363/en/ 

 https://www.alnylam.com/alnylam-rnai-pipeline/ 

 https://seekingalpha.com/symbol/VIR 

 https://seekingalpha.com/symbol/ALNY 

Wed February 19, 2020 7:00 AM|Business Wire|About: DXCM, PODD

• First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control
• Initially compatible with Dexcom G6 CGM, with no fingersticks* required
• Integration with the next generation Dexcom G7 CGM system, once available

SAN DIEGO & ACTON, Mass.--(BUSINESS WIRE)-- DexCom (DXCM), Inc. (NASDAQ: DXCM) and Insulet Corporation (PODD)

 http://www.insulet.com/ 

 https://www.myomnipod.com/home 

 https://www.businesswire.com/news/home/20200219005028/en/ 

 https://seekingalpha.com/symbol/DXCM 

 https://seekingalpha.com/symbol/PODD 

Feb. 24, 2020 8:16 AM ET|About: CytomX Therapeutics, Inc. (CTMX)|By: Liz Kiesche, SA News Editor 

 https://cytomx.com/ 

 https://cytomx.com/pipeline/ 

 https://seekingalpha.com/symbol/CTMX 

Tue February 25, 2020 8:25 AM|PR Newswire|About: JNJ

PR Newswire

NEW BRUNSWICK, N.J., Feb. 25, 2020 /PRNewswire/ -- Johnson & Johnson (JNJ)

 https://www.heartline.com/ 

Heart Health Education

New Brunswick, NJ, February 25, 2020 — Johnson & Johnson (NYSE: JNJ)

 https://www.multivu.com/players/English/8693251-heartline-study/ 

 https://www.jnj.com/ 

 https://www.prnewswire.com/news-releases/johnson--johnson-launches-heartline-the-first-of-its-kind-virtual-study-designed-to-explore-if-a-new-iphone-app-and-apple-watch-can-help-reduce-the-risk-of-stroke-301010792.html 

 https://seekingalpha.com/symbol/JNJ 

Wed February 26, 2020 2:00 AM|Business Wire|About: TAK

− Investigational medicine TAK-062 is an oral computationally engineered super glutenase designed to improve the digestion of gluten

− Successful “build to buy” relationship adds second investigational therapy to Takeda’s pipeline for the potential treatment of uncontrolled celiac disease

OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TKPHF) (TSE:4502/NYSE:TAK) 

October 22, 2019 

 https://www.takeda.com/newsroom/newsreleases/2019/takeda-acquires-license-for-first-in-class-celiac-disease-therapy-from--cour-pharmaceuticals-following-positive-phase-2a-proof-of-concept-study/ 

 https://www.takeda.com/ 

 https://www.niddk.nih.gov/health-information/digestive-diseases/celiac-disease/symptoms-causes 

 https://www.businesswire.com/news/home/20200225005816/en/ 

 https://www.pvpbio.com/ 

 https://seekingalpha.com/symbol/TAK 

Wed February 26, 2020 8:30 AM|GlobeNewswire|About: AMGN, CYTK

Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure Continue without Changes

Topline Results Expected in Q4 2020

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier

 https://www.amgen.com/ 

 https://cytokinetics.com/ 

 https://servier.com/en/ 

Thu February 27, 2020 4:06 PM|Business Wire|About: BIIB, SGMO

• Broad collaboration for gene regulation therapies in neurology, initially focused on development of ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, and a neuromuscular target, with exclusive rights for nine additional undisclosed neurological targets
• Biogen will pay Sangamo $350 million upfront, including a license fee and an equity investment in Sangamo stock
• Sangamo is eligible to receive up to $2.37 billion in potential milestones, as well as royalties on potential net commercial sales
• Biogen’s access to Sangamo's gene regulation therapies complements its expanding efforts in gene therapy across diverse neurological diseases

CAMBRIDGE, Mass. & BRISBANE, Calif.--(BUSINESS WIRE)-- Biogen Inc. (BIIB) and Sangamo Therapeutics, Inc. (SGMO),

 https://www.businesswire.com/news/home/20200227005961/en/ 

Sangamo and Biogen Neurology Collaboration

February 27, 2020

 https://investor.sangamo.com/static-files/81a67847-1710-4716-9e98-4fb798cbef8a 

 https://www.biogen.com/ 

 https://www.sangamo.com/ 

 https://seekingalpha.com/symbol/BIIB 

 https://seekingalpha.com/symbol/SGMO 

Tue February 18, 2020 10:00 AM|GlobeNewswire|About: SNY

Sanofi (SNY) joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine

*Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi’s well-established recombinant technology platform to expedite a potential COVID-19 vaccine

PARIS – February 18, 2020 – Sanofi Pasteur,

 https://www.sanofi.com/ 

 https://www.sanofi.com/en/media-room/press-releases/2020/2020-02-18-16-00-00 

 https://seekingalpha.com/symbol/SNY 

Tue February 18, 2020 9:30 AM|PR Newswire|About: JNJPR Newswire

NEW BRUNSWICK, N.J., Feb. 18, 2020 /PRNewswire/ -- Johnson & Johnson (JNJ)

 https://www.jnj.com/johnson-johnson-launches-multi-pronged-response-to-coronavirus-global-public-health-threat 

 https://www.jnj.com/johnson-johnson-announces-collaboration-with-u-s-department-of-health-human-services-to-accelerate-development-of-a-potential-novel-coronavirus-vaccine 

 https://www.jnj.com/coronavirus 

 https://www.jnj.com/ 

 https://www.janssen.com/ 

 https://www.prnewswire.com/news-releases/johnson--johnson-to-expand-partnership-with-us-department-of-health--human-services-to-accelerate-the-discovery-of-potential-covid-19-treatments-301006642.html 

 https://seekingalpha.com/symbol/JNJ 

Tue February 18, 2020 10:00 AM|Newsfile|About: JNJNewsfile Corp

San Diego, California--(Newsfile Corp. - February 18, 2020) - DNX Biopharmaceuticals, a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases and a resident of Johnson & Johnson Innovation - JLABS, Shanghai

 http://www.dnxbio.com/index2.html 

 https://jlabs.jnjinnovation.com/quickfire-challenges/lung-cancer-innovation-quickfire-challenge 

 https://www.newsfilecorp.com/release/52493 

Tue February 4, 2020 2:34 PM|Canada Newswire|About: TAK

FOR CANADIAN AUDIENCES ONLY

Takeda Canada will invest $2.4 million in this important study which aims to evaluate real world outcomes in lung cancer patients

TORONTO, Feb. 4, 2020 /CNW/ - Takeda Canada Inc. is pleased to support the CAnadian CAncers with Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) - CARMA-BROS – in collaboration with Princess Margaret Cancer Centre, part of the University Health Network.

 https://seekingalpha.com/symbol/TKPHF 

 https://www.takeda.com/en-ca 

Tue February 18, 2020 5:42 AM|PR Newswire|About: WXXWY

SHANGHAI, Feb. 18, 2020 /PRNewswire/ -- WuXi Biologics (WXXWY) ("WuXi Bio") (2269.HK)

 https://www.wuxibiologics.com/ 

 https://www.prnewswire.com/news-releases/wuxi-biologics-subsidiary-wuxi-vaccines-signed-long-term-vaccine-manufacturing-contract-with-a-global-vaccine-leader-301006453.html 

 https://seekingalpha.com/symbol/WXXWY 

 SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. 

 http://www.hile-bio.com/ 

Wed February 19, 2020 6:30 AM|PR Newswire|About: ABT, PODD

PR Newswire

ABBOTT PARK, Ill. and ACTON, Mass., Feb. 19, 2020 /PRNewswire/ -- Abbott (ABT) and Insulet Corporation (PODD)

 Nov 20, 2018

The Only Insulin Pump to Receive Both ISO 27001 and DTSec Certifications

BILLERICA, Mass.--(BUSINESS WIRE)--Nov. 20, 2018-- Insulet Corporation (NASDAQ: PODD)

 http://investor.insulet.com/news-releases/news-release-details/insulets-omnipod-dashtm-insulin-management-system-receives-iso 

 https://www.diabetestechnology.org/dtsec.shtml?ver=4 

 http://www.insulet.com/ 

 https://www.myomnipod.com/home 

 https://www.freestylelibre.us/safety-information.html 

 https://www.abbott.com/ 

 https://www.prnewswire.com/news-releases/abbott-and-insulet-partner-to-integrate-next-generation-glucose-sensing-and-automated-insulin-delivery-technologies-for-seamless-diabetes-care-301007119.html 

 https://seekingalpha.com/symbol/PODD 

 https://seekingalpha.com/symbol/ABT